2022 Volume 6 Issue 4 Pages 221-230
Robotic surgical systems were created in part to solve several constraints of laparoscopic surgery and offer technical advantages. With a substantial body of evidence that demonstrates its efficacy in the treatment of rectal cancer, robotic surgery will soon become another conventional treatment. However, further investigations and randomized trials focusing on primary endpoints are needed to establish some advantages for robot-assisted colon surgery. Da Vinci Single-Site® and SP® platforms were developed to overcome the shortcomings of single-port laparoscopic surgery. Despite the currently insufficient evidence, it appears that the SP platform addresses many of the limitations of single-port transabdominal or transanal surgery. Robotic transanal minimally invasive surgery and total mesorectal excision were developed to overcome some of the limitations of conventional platforms, using wristed instrumentation to enhance dexterity and ergonomics. Studies on the effectiveness and viability of this novel approach are ongoing. The near-infrared fluorescence technique, real-time stereotactic navigation technology, and other surgical data platforms based on artificial intelligence incorporated into the robotic system will play an important role in improving outcomes. Robotic systems for advanced colorectal cancer offer technical advantages for complex and precise surgeries. If the cost of robotic surgery is reduced by expanding its indications and enhancing competition among different robotic platforms, it will provide clinical benefits to more patients and reduce social healthcare costs.